A Phase II Evaluation of Liposomal Doxorubicin (Doxil) in the Treatment of Persistent or Recurrent Squamous Cell Carcinoma of the Cervix
OBJECTIVES:
- Determine the antitumor activity of doxorubicin HCl liposome in patients with
persistent or recurrent squamous cell carcinoma of the cervix.
- Determine the toxicity of this drug in these patients.
OUTLINE: This is a multicenter study.
Patients receive doxorubicin HCl liposome IV over 1 hour on day 1. Treatment repeats every
28 days in the absence of disease progression or unacceptable toxicity.
Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then
annually thereafter.
PROJECTED ACCRUAL: A total of 22-60 patients will be accrued for this study.
Interventional
Primary Purpose: Treatment
Peter G. Rose, MD
Study Chair
MetroHealth Cancer Care Center at MetroHealth Medical Center
United States: Federal Government
CDR0000069168
NCT00030472
December 2001
Name | Location |
---|---|
Roswell Park Cancer Institute | Buffalo, New York 14263 |
Jonsson Comprehensive Cancer Center, UCLA | Los Angeles, California 90095-1781 |
MBCCOP - Hawaii | Honolulu, Hawaii 96813 |
State University of New York Health Sciences Center - Stony Brook | Stony Brook, New York 11790-7775 |
Lineberger Comprehensive Cancer Center, UNC | Chapel Hill, North Carolina 27599-7295 |
Abington Memorial Hospital | Abington, Pennsylvania 19001 |
Community Hospital of Los Gatos | Los Gatos, California 95032 |
University of Texas Medical Branch | Galveston, Texas 77555-1329 |
Holden Comprehensive Cancer Center at University of Iowa | Iowa City, Iowa 52242-1002 |
Charles M. Barrett Cancer Center at University Hospital | Cincinnati, Ohio 45267-0526 |
Cleveland Clinic Taussig Cancer Center | Cleveland, Ohio 44195 |
Cooper University Hospital | Camden, New Jersey 08103 |
Tufts - New England Medical Center | Boston, Massachusetts 02111 |
Fletcher Allen Health Care - Medical Center Campus | Burlington, Vermont 05401 |
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support | Bethesda, Maryland 20892-1182 |
University of Texas M.D. Anderson CCOP Research Base | Houston, Texas 77030-4009 |